These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 20017601)

  • 1. Pharmaceutical development of microbicide drug products.
    Friend DR
    Pharm Dev Technol; 2010 Dec; 15(6):562-81. PubMed ID: 20017601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel approaches to vaginal delivery and safety of microbicides: biopharmaceuticals, nanoparticles, and vaccines.
    Whaley KJ; Hanes J; Shattock R; Cone RA; Friend DR
    Antiviral Res; 2010 Dec; 88 Suppl 1():S55-66. PubMed ID: 21109069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in development, scale-up and manufacturing of microbicide gels, films, and tablets.
    Garg S; Goldman D; Krumme M; Rohan LC; Smoot S; Friend DR
    Antiviral Res; 2010 Dec; 88 Suppl 1():S19-29. PubMed ID: 21109064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining prevention of HIV-1, other sexually transmitted infections and unintended pregnancies: Development of dual-protection technologies.
    Friend DR; Doncel GF
    Antiviral Res; 2010 Dec; 88 Suppl 1():S47-54. PubMed ID: 21109068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in microbicide vaginal rings.
    Malcolm RK; Edwards KL; Kiser P; Romano J; Smith TJ
    Antiviral Res; 2010 Dec; 88 Suppl 1():S30-9. PubMed ID: 21109066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microbicide delivery: formulation technologies and strategies.
    Romano J; Malcolm RK; Garg S; Rohan LC; Kaptur PE
    Curr Opin HIV AIDS; 2008 Sep; 3(5):558-66. PubMed ID: 19373022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of topical microbicides to prevent HIV-1 transmission: concepts, testing, lessons learned.
    Friend DR; Kiser PF
    Antiviral Res; 2013 Sep; 99(3):391-400. PubMed ID: 23845918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide.
    Woolfson AD; Malcolm RK; Morrow RJ; Toner CF; McCullagh SD
    Int J Pharm; 2006 Nov; 325(1-2):82-9. PubMed ID: 16884869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should microbicides be controlled by women or by physicians?
    Piret J; Bergeron MG
    Int J Infect Dis; 2010 Sep; 14 Suppl 3():e14-7. PubMed ID: 20932483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microbicide dosage forms.
    Rohan LC; Devlin B; Yang H
    Curr Top Microbiol Immunol; 2014; 383():27-54. PubMed ID: 24220751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained release of microbicides by newly engineered vaginal rings.
    Saxena BB; Han YA; Fu D; Rathnam P; Singh M; Laurence J; Lerner S
    AIDS; 2009 May; 23(8):917-22. PubMed ID: 19381077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is HIV drug resistance a limiting factor in the development of anti-HIV NNRTI and NRTI-based vaginal microbicide strategies?
    Martinez J; Coplan P; Wainberg MA
    Antiviral Res; 2006 Sep; 71(2-3):343-50. PubMed ID: 16787667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Electrospun fibers for vaginal anti-HIV drug delivery.
    Blakney AK; Ball C; Krogstad EA; Woodrow KA
    Antiviral Res; 2013 Dec; 100 Suppl():S9-16. PubMed ID: 24188701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibiting sexual transmission of HIV-1 infection.
    Shattock RJ; Moore JP
    Nat Rev Microbiol; 2003 Oct; 1(1):25-34. PubMed ID: 15040177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Future strategies in microbicide development.
    Rosenberg ZF; Devlin B
    Best Pract Res Clin Obstet Gynaecol; 2012 Aug; 26(4):503-13. PubMed ID: 22406260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanoparticle-based vaginal drug delivery systems for HIV prevention.
    Mallipeddi R; Rohan LC
    Expert Opin Drug Deliv; 2010 Jan; 7(1):37-48. PubMed ID: 20017659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Historical development of vaginal microbicides to prevent sexual transmission of HIV in women: from past failures to future hopes.
    Notario-Pérez F; Ruiz-Caro R; Veiga-Ochoa MD
    Drug Des Devel Ther; 2017; 11():1767-1787. PubMed ID: 28670111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nano-microbicides: challenges in drug delivery, patient ethics and intellectual property in the war against HIV/AIDS.
    du Toit LC; Pillay V; Choonara YE
    Adv Drug Deliv Rev; 2010 Mar; 62(4-5):532-46. PubMed ID: 19922751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current status of topical antiretroviral chemoprophylaxis.
    Van Damme L; Szpir M
    Curr Opin HIV AIDS; 2012 Nov; 7(6):520-5. PubMed ID: 22918449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.